Among 2752 patients with acute leukemia who had recurrent leukemia after autograft in remission and were reported to the EBMT, 94 underwent an allogeneic bone marrow transplant and 74 received a second autograft. Recipients of HLA-mismatched related or unrelated bone marrow had an increased transplant-related mortality (TRM, P = 0.017) and a decreased leukemiafree survival (LFS, P = 0.03), compared to recipients of HLA matched related or unrelated bone marrow. Outcome in recipients of HLA-compatible related or unrelated bone marrow was compared to those receiving a second autograft. TRM at 2 years was 51 ؎ 8% in recipients of matched allografts and 26 ؎ 6% following a 2nd autograft (P Ͻ 0.05). Two-year LFS was 27 ؎ 7% and 35 ؎ 6% in the two groups, respectively (NS). Multivariate analysis in these two groups showed that TRM was increased in patients who were in 2nd or later remission at 1st autograft (P Ͻ 0.05) and allograft recipients (P Ͻ 0.05). Relapse was more common in patients with ALL (P Ͻ 0.001), above 25 years of age (P Ͻ 0.02), autograft performed later than 1991 (P Ͻ 0.05), and in second autografts (P Ͻ 0.05). LFS was decreased in patients Ͼ25 years of age (P Ͻ 0.01), if the interval from first autograft to relapse was 8 months or less (P Ͻ 0.01) and if TBI was used at first autograft (P Ͻ 0.05). Keywords: bone marrow transplantation; acute leukemia; allograft; autograft; relapse In patients with high-risk acute leukemia, intensive chemotherapy, with or without whole body irradiation, followed by allogeneic or autologous bone marrow rescue is used with the intention to cure.
versus-leukemia effect resulting in a decreased risk of relapse. [5] [6] [7] However, the risk of transplant-related complications, such as graft-versus-host disease (GVHD), infections and toxic side-effects results in a higher transplantrelated mortality (TRM) in BMT, than with autografts. 4, 8, 9 Up to half of the patients who undergo autografting for acute leukemia relapse and only a fraction are cured. Patients who relapse after high-dose chemotherapy and autografting have a poor prognosis. [2] [3] [4] 8, 10 This study was performed to evaluate the outcome in patients with acute leukaemia who relapsed after autograft and underwent a second transplantation procedure. Furthermore, we wanted to see whether these patients tolerated a second round of high-dose chemotherapy with or without irradiation and to compare their outcome following BMT vs a second autograft.
Patients and methods

Patients
All patients undergoing autologous transplantation for acute leukemia between 1 January 1981 and 31 December 1996 and who were reported to the Acute Leukaemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT), and had a second graft after a relapse were included in the study. Only patients autografted in remission at first autograft were included. Follow-up time was a median of 35 months (range 5-137) from first autograft. Time from relapse was 20 months .
Characteristics of patients undergoing: (A) matched BMT, or (B) second autograft are given in Table 1 .
Several characteristics did not differ significantly between the groups, including remission status at second transplant in group A, 59% being in complete remission (CR), compared to 54% in group B. However, there were significantly more patients with acute lymphoblastic leukaemia (ALL) in group A, than in group B. Transplants had been performed more recently in those receiving allografts, compared to second autografts (P Ͻ 0.0001). Total body irradiation (TBI) at first autograft was more commonly used in group A, and peripheral blood (PB) as a source of stem cells was more common in group B. The interval from relapse to second transplant was longer in group A than in group B (P = 0.0002). At second transplant, a TBI-containing regimen was given more often to the allograft recipients than to the second autograft recipients (P = 0.0005).
Donors and immunosuppression
Among the allogeneic donors there were 26 HLA-identical siblings, one syngeneic donor and two HLA-identical parents. HLA typing was serologic and genomic methods were increasingly used for class II typing in more recent years. Fourteen HLA-mismatched family donors were also used. Among the unrelated donors, 33 were HLA-A, -B and -DR compatible and six were mismatched. In the primary analysis, patients receiving grafts from HLA-identical related or HLA-compatible unrelated and -mismatched donors were analyzed separately. For comparison with second autografts, only recipients of bone marrow from related HLA-identical donors and recipients of unrelated HLA-compatible bone marrow were analyzed, because of the poor outcome in the HLA mismatches. In the recipients of HLA-matched marrow, immunosuppression consisted of cyclosporine in six, cyclosporine combined with methotrexate in 34, T cell depletion in five and information was lacking in 17. [11] [12] [13] [14] In recipients of HLA-mismatched grafts, cyclosporine alone was given to three, cyclosporine and methotrexate to three, T cell depletion to six and information was not available in eight.
Statistical analyses
All analyses were performed with the SPSS statistical package. Kaplan-Meier curves for TRM, relapse, leukemia-free survival (LFS) and patient survival were calculated with the product limit method, according to Kaplan and Meyer. 15 Survival and relapse were calculated from the time of relapse after the first autograft. The significance of differences between the curves was estimated by the log-rank test (Mantel-Cox). Cox multivariate regression analysis was performed in the various groups to estimate the independent effects of various potential risk factors in TRM, relapse, survival and LFS. 16 All factors differing significantly between groups A and B and/or prognostic factors in one group at the time of the first autograft are included. Factors in the multivariate analysis are: group A vs B, diagnosis ALL vs AML, year of transplant 1991 or earlier vs later (median), age at the time of first autograft: р25 years vs Ͼ25 (median age), patient gender, remission status at first autograft (CR-1 vs CR-2 ϩ 3), interval from first autograft to relapse р8 vs Ͼ8 months (median), pretransplant regimen, including TBI or not, (first graft), source of stem cells (PB versus marrow, first graft) remission status at second transplant (CR vs no CR) and interval from relapse to second transplant (median 5 months).
Results
Outcome in recipients of allografts according to HLA matching
The probability of grades II-IV acute GVHD was 56 Ϯ 9% (mean Ϯ 95% confidence interval) in recipients of HLAidentical related bone marrow (n = 29), compared to 53 Ϯ 10% in recipients of marrow from HLA-compatible unrelated donors (n = 33). In recipients of marrow from HLA-mismatched related or unrelated bone marrow (n = 20), the cumulative incidence of acute GVHD was 24 Ϯ 9%. TRM was significantly higher in recipients of HLA-mismatch related or unrelated marrow than in those receiving HLA-identical related or HLA-compatible unrelated marrow ( Figure 1 ). LFS was also decreased in patients receiving HLA-mismatched marrow (P = 0.03, Figure 2 ).
Overall outcome in recipients of matched allografts (group A) or 2nd autografts (group B)
TRM at 2 years was 51 Ϯ 8% in group A and 26 Ϯ 6% in group B (P = 0.036). The 2 year relapse probability was 44 Ϯ 10%, compared to 53 Ϯ 7%, in the two groups, respectively (P = 0.11). The overall 2-year LFS was 27 Ϯ 7% in group A (n = 62) and 35 Ϯ 6% in group B (P = 0.77). Patients with ALL who received an allograft (n = 27) had an increased TRM, 40 Ϯ 2% at 1 year, compared to 7 Ϯ 6% in those receiving a second autograft (n = 18, P = 0.023). AML patients receiving a second autograft (n = 56) had a significantly higher relapse incidence of 50 Ϯ 8% at 2 years, compared to 15 Ϯ 8% for those given an HLA-matched allograft (n = 35, P = 0.11). Adults (у18 years of age) receiving allogeneic marrow (n = 40) had a higher TRM (66 Ϯ 8% vs 31 Ϯ 7% at 2 years, P = 0.006) and a lower relapse incidence (30 Ϯ 13% vs 64 Ϯ 8%, P = 0.032), compared to second autograft recipients. Otherwise, there were no significant differences in groups A and B regarding TRM, relapse, survival and LFS in the subgroups with ALL, AML, adults and children.
Time from relapse to transplant was longer for allo-compared to autograft recipients (P = 0.0003, Table 1 ). Patients receiving an allograft or a second autograft before 5 months of relapse had similar outcomes (Table 2) . However, if the transplant was performed 5 months or later after relapse, allograft recipients had an increased TRM and decreased survival and LFS, compared to recipients of second autografts.
If the second autograft was collected before first transplant (n = 33), 2-year relapse probability was 69 Ϯ 9%, compared to 22 Ϯ 10% if the autograft was collected before the second autograft (n = 26, P = 0.01). Two-year LFS was 21 Ϯ 7% and 55 Ϯ 10% in the two groups, respectively (P = 0.03). There was a strong correlation between harvest before second autograft and remission 22/85 (85%), compared to no reharvest 6/33 (18%) (P Ͻ 0.001).
Causes of death
Recurrent disease was the most common cause of death and was more common in group B than in group A (Table 3) . Deaths due to complications, such as infections or toxicity, were more common in group A.
Risk factor analysis in patients receiving a matched allograft
In group A, patients with ALL ran a higher risk of relapse than those with AML undergoing allogeneic transplantation (Table 4) . Females had an increased TRM and a decreased survival and LFS. Those treated with TBI at first autograft had an increased TRM, increased probability of relapse, a decreased survival and LFS. Patients below 25 years of age had a lower TRM than older patients. If the interval from first autograft to relapse was 7 months or less, the probability of relapse was increased and LFS was decreased. No factor was significant for outcome at second transplant in group A.
Risk factor analysis in patients receiving a second autograft
Among patients in group B, those with AML had an increased TRM (Table 5) . Patients above 26 years of age had a lower survival and LFS. If the interval from first autograft to relapse was 7 months or shorter, LFS was decreased.
At second autograft, the following factors were significantly associated with outcome. If the interval from relapse to second autograft was 3 months or less, the incidence of relapse was increased and the probabilities of survival and LFS were also increased (Table 5) . Patients who were in remission had a significantly better survival and LFS. 
Comparison is based on the interval between relapse and second transplant more or less than the median (5 months).
Table 3
Causes of death in patients who had a relapse after first autograft in remission for acute leukemia. Subsequently, the patients underwent (A) BMT or (B) a second autograft Multivariate analysis of outcome TRM was higher in patients who were in second or third CR at first autograft and in allograft recipients ( Table 6 ). The incidence of relapse was significantly increased in patients with ALL, in older patients, in those undergoing the first autograft after 1991 and in group B vs group A. Poor survival and LFS rates were seen in older patients, if the interval from the first autograft to relapse was 8 months or less and if TBI was included in conditioning during the first autograft.
Outcome in relation to TBI
In patients receiving TBI at the first autograft, LFS was significantly better in those undergoing a second autograft than for those receiving an HLA-matched allograft ( Figure  3) . Ten of the patients in groups A and B were conditioned twice with TBI. One of seven in group A is alive 17 months after relapse and 2/3 in group B are alive after 29 and 50 months. Patients not treated with TBI at first autograft tended to have a better LFS in group A vs group B (P = 0.08, Figure 4 ).
Discussion
Patients with acute leukemia and recurrent disease after an autograft have a very poor outcome. Patients treated with chemotherapy or palliative therapy have an on-going reduction in survival with an expected survival of around 10% at 2 years. 17 In an attempt to change this dismal outcome, we performed an allograft transplant or a second autograft in some patients. These options are not open to all patients. To perform an allograft, a suitable donor must be available. To perform a second autograft, it must be possible to collect sufficient stem cells. Both procedures introduce selection biases. A search for an unrelated donor took an average of 6 months resulting in exclusion of some high-risk patients with early relapse. However, with a second autograft, mainly patients with a suitable marrow harvest are included. This was more likely to be in patients in CR who also had a better prognosis. There was a close correlation between remission at second autograft and reharvest (P = 0.0001). In contrast, patients who were not in remission at second autograft more often received a graft that was collected before first autograft. Therefore, patients who received autografts harvested before first autograft had a worse outcome.
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Table 4
Patients in group A autografted in CR1, CR2, CR3ϩ and subsequently receiving marrow from a matched related or unrelated donor (n = 62). Prognostic factors on outcome after first relapse Results are given at 1 year because of the small number of patients at risk at 2 years (% Ϯ 95% confidence interval) and P values.
In the study of patients treated with allografts, those receiving HLA-mismatched related or unrelated bone marrow had a high TRM and a low LFS, compared to those receiving HLA-matched related or unrelated bone marrow (Figures 1 and 2 ). This is in keeping with previous studies. 13, 18, 19 The poorer outcome with HLA-mismatched transplants is generally due to an increased risk of severe GVHD. However, in the present analysis, there was no significant difference in GVHD between recipients of HLAmismatched or matched bone marrow. The reason for this may be that recipients of HLA-mismatched marrow were more often treated with T cell-depleted transplants, 50% compared to 11% in the matched patients. It is well known that T cell depletion reduces the risk of GVHD, but this may be offset by an increased risk of graft failure, infections and leukemic relapse. 13, 14 Because of the poor outcome in recipients of HLA-mismatched marrow, these patients were excluded from further analysis.
In the present analysis, there was no difference in GVHD, TRM and LFS between recipients of HLA-matched unrelated or related bone marrow (Figures 1 and 2 ). This is in contrast to most studies, which show an increased risk of GVHD, TRM and a decreased probability of LFS in recipients of HLA-matched unrelated bone marrow, compared to HLA-identical sibling marrow. [20] [21] [22] [23] The findings in the present analysis should be interpreted with caution, because of the small number of patients included. Therefore, the similar outcomes, and, for convenience, matched unrelated and related allograft recipients were analyzed together. In a subsequent analysis regarding probability of TRM, relapse and LFS, these patients were compared to recipients of second autografts. Patients given chemotherapy or palliative therapy alone were not included, because of insufficient data. Only survival data were available in these. Patients undergoing a second autograft had significantly better survivals than those treated with chemotherapy alone. 17 This indicates that a more active approach is worthwhile.
With regard to TRM, patients in second or later remission at first autograft had a worse outcome, which is not unexpected and is in line with the experience at first transplants. [2] [3] [4] 8, 24 Patients in late remission have been 394 allo matched (n = 36) P = 0.0078 Figure 3 Leukemia-free survival (LFS) in patients who received total body irradiation (TBI) at first autograft and subsequently received a second autograft (auto) or an HLA-matched related or unrelated allograft (allo). % Ϯ 95% confidence interval 1 and 2 years after relapse. NA = not assessible. 
Figure 4
Leukemia-free survival (LFS) in patients not treated with total body irradiation (TBI) at first autograft and who subsequently received a second autograft (auto) or HLA-identical related or unrelated bone marrow (allo-matched). % Ϯ 95% confidence interval is given at 1 and 2 years after relapse of first autograft.
treated with more cytotoxic drugs and are at an increased risk of toxicity and death when treated with two subsequent transplants, including heavy conditioning. Allograft recipients had a higher TRM, as in previous reports. 4, 8, 9 Relapse was significantly increased in patients with ALL vs AML. This may be partly due to the fact that 11/33 ALL patients received busulfan ϩ cyclophosphamide at second transplant. This conditioning has been reported to increase the risk of relapse compared to TBI in autograft recipients with ALL. 25 Recipients of second autografts ran an increased risk of relapse, compared to allograft recipients, which is not surprising and is in accordance with comparative studies of first transplants with autografts vs allografts. 4, 8, 9, 26, 27 Autografts performed more recently had a higher risk of relapse. With an increasing number of autografts performed, more high-risk patients were accepted. That patients with a short interval from first autograft to relapse had a worse outcome may be expected. Those with an early relapse have a resistant cell clone with a high probability of subsequent relapse even after a second transplant. Early relapse at first autograft had an effect on survival and LFS although this was not significant for relapse in the multivariate analysis. Younger patients had a better survival and LFS, which is in accordance with previous studies in patients undergoing primary allografts. 24 Young patients tolerate the conditioning better and therefore run less risk of TRM. This must be especially evident in patients undergoing two subsequent procedures with heavy myeloablative therapy.
TBI was an important risk-factor, and patients treated with TBI at the first autograft had a poor outcome, especially if they underwent a subsequent allo-transplant (Tables 2 and Table 4 , Figure 3 ). To explain this, several factors must be taken into consideration. In univariate analysis, TBI was a risk factor for TRM and relapse in patients treated with a subsequent allograft, but not a second autograft (Table 3 and 4). The higher TRM may be affected by the high death rate, 6/7, in group A patients receiving two rounds of TBI, so it probably should be avoided. The higher relapse rate in the TBI group may also be due to the fact that this is a selected group of patients with a more or less therapy-resistant leukemic cell clone. Some of these patients had ALL and busulfan may be inferior at a second transplant procedure, as was found in primary autografts. 25 One cannot perform further subgroup analyses to evaluate the role of diagnoses, conditioning, type of graft, etc, because of the small number of patients.
In decision-making for treatment of patients with acute leukemia who relapse after autografting, the risk factors found in this study may give some guidelines. When should a second transplant procedure be tried? Preferably in young patients who relapse Ͼ8 months after autografting. If one can choose between an HLA-matched donor transplant or viable autologous stem cells, which should be favored? If TBI was used at first autograft, a second autograft may be favored. If TBI was not used, a matched allograft should be considered ( Figures 3 and 4 , Table 6 ). If a matched donor is not available within 5 months after relapse, a second autograft may be more appropriate (Table 2) .
